Q92793 (CBP_HUMAN) Homo sapiens (Human)
CREB-binding protein UniProtKBProtein AtlasInterProSTRINGInteractive Modelling
2442 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
134 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 1 |
Heteromer P04908; P06899; P62805; P68431; | 100.0 | ||||
| Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 3 |
Heteromer P04908; P06899; P62805; P68431; | 100.0 | ||||
| Cryo-EM structure of the CBP catalytic core bound to the H4K12acK16ac nucleosome, class 2 |
Heteromer P04908; P06899; P62805; P68431; | 100.0 | ||||
| Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in… |
Heteromer P62805; | 100.0 | 2×ZN; | |||
| Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in… |
Heteromer P62805; | 100.0 | 2×ZN; | |||
| NMR Structure of CBP Bromodomain in complex with p53 peptide |
Heteromer P04637; | 100 | ||||
| Complex Structures of CBP Bromodomain with H4 ack20 Peptide |
Heteromer P62805; | 100 | ||||
| Crystal structure of CBP Bromodomain with H3K56ac peptide |
Heteromer P68431; | 100 | ||||
| NMR structure of CBP TAZ2 and adenoviral E1A complex |
Heteromer P03255; | 100 | 3×ZN; | |||
| Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic c… |
Heteromer Q03164; | 100 | ||||
| Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic c… |
Heteromer P16220; Q03164; | 100 | ||||
| The structure of E-protein activation domain 1 bound to the KIX domain of CBP/p300 elucidates leuke… |
Heteromer P15884; | 100 | ||||
| Crystal structure of the KIX domain of CBP in complex with a MLL/c-Myb chimera |
Heteromer P01103; Q03164; | 100 | 2×GOL; 7×CL; | |||
| cryo-EM structure of MBP-KIX-apoferritin complex with peptide 7 |
Heteromer P09528; P16220; | 97.22 | ||||
| Crystal structure of complex between nuclear coactivator binding domain of CBP and [1040-1086]ACTR … |
Heteromer P0AEX9; Q9Y6Q9; | 100 | 1×GLC; 1×EDO; 2×ZN; | |||
| Docked structure between SUMO1 and ZZ-domain from CBP |
Heteromer P63165; | 100 | 2×ZN; | |||
| Structure and dynamics conspire in the evolution of affinity between intrinsically disordered prote… |
Heteromer Q9Y6Q9; | 100 | ||||
| Structure and dynamics conspire in the evolution of affinity between intrinsically disordered prote… |
Heteromer | 91.67 | ||||
| IRF3-CBP complex |
Heteromer Q14653; | 100 | ||||
| Structure and dynamics conspire in the evolution of affinity between intrinsically disordered prote… |
Heteromer | 84.44 | ||||
| Complex of IRF-3 with CBP |
Heteromer Q14653; | 100 | ||||
| Crystal structure of mouse phosphorylated IRF-3 bound to CBP |
Heteromer P70671; | 100 | ||||
| Crystal structure of human phosphorylated IRF-3 bound to CBP |
Heteromer Q14653; | 100 | ||||
| Crystal structure of SMAD2 in complex with CBP |
Heteromer Q15796; | 94.44 | ||||
| Crystal structure of SMAD2 in complex with wild-type CBP |
Heteromer Q15796; | 100 | ||||
| Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 |
Heteromer P37231; | 100 | 2×EDK; | |||
| Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPA… |
Heteromer P19793; P37231; Q15788; | 100 | 1×L79; 1×570; | |||
| cryo-EM structure of MBP-KIX-apoferritin | homo-24-mer | 97.22 | ||||
| Crystal structure of CBP bromodomain liganded with Y08284 | homo-2-mer | 100 | 2×GHF; 1×GOL; | |||
| Crystal structure of the CBP bromodomain in complex with small molecule LC-CPin7 | homo-2-mer | 100 | 1×EOO; 4×NA; | |||
| Crystal structure of CBP bromodomain liganded with Y08092(31g) | homo-2-mer | 100 | 2×GI5; 1×GOL; 1×PEG; | |||
| CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-… | monomer | 100.0 | 3×ZN; 1×69E; 1×B3P; 5×EDO; 1×NA; 2×PEG; | |||
| CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]… | monomer | 100.0 | 3×ZN; 1×69F; 1×B3P; 5×EDO; 1×NA; 1×PEG; | |||
| CREBBP bromodomain in complex with Cpd 30 (1-(3-(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl)-1-(t… | monomer | 100.0 | 3×ZN; 1×B3P; 1×BKJ; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound | monomer | 100 | 1×6F9; 3×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with UN32 | monomer | 100 | 1×5QR; | |||
| CBP-BrD complexed with NEO2734 | monomer | 100 | 1×7OW; | |||
| Crystal structure of CREBBP bromodomain complexd with US46C | monomer | 100 | 1×8Q6; | |||
| Crystal structure of CREBBP bromodomain complexed with CBP019 | monomer | 100 | 1×QPR; | |||
| Bromodomain of CBP liganded with iCBP6 | monomer | 100 | 1×YID; 2×EDO; | |||
| Crystal Structure Analysis of the CBP | monomer | 100 | 1×E0D; 1×EDO; 1×MG; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand | monomer | 100 | 3×EDO; 1×K; 1×3PF; | |||
| Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c | monomer | 100 | 1×71X; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with UO37D | monomer | 100 | 1×5XS; | |||
| Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP | monomer | 100 | 1×99E; 4×BU3; 1×SO4; | |||
| Structure of bromodomain of CREBBP with a pyrazolo[4,3-c]pyridin fragment | monomer | 100 | 1×77X; 1×EDO; | |||
| Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand | monomer | 100 | 2×KRG; 1×EDO; | |||
| Crystal structure of CBP bromodomain liganded with Y08175 | monomer | 100 | 1×EJ3; 1×DMS; 2×GOL; | |||
| Crystal structure of CREBBP bromodomain complexd with PA10 | monomer | 100 | 1×E3T; | |||
| BROMO domain of CREB binding protein | monomer | 100 | 1×3OT; | |||
| Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand | monomer | 100 | 1×OSN; | |||
| Solution NMR structures of CBP bromodomain with small molecule j28 | monomer | 100 | 1×J28; | |||
| Solution NMR structures of CBP bromodomain with small molecule of HBS | monomer | 100 | 1×L85; | |||
| Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein (… | monomer | 100 | 1×TTR; | |||
| Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand | monomer | 100 | 1×2O4; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole li… | monomer | 100 | 3×EDO; 1×2LO; | |||
| Crystal structure of CREBBP bromodomain complexed with FA26 | monomer | 100 | 2×YE5; 2×EDO; | |||
| Crystal structure of CREBBP bromodomain complexed with CBP015 | monomer | 100 | 1×F31; | |||
| Crystal structure of CREBBP bromodomain complexd with DR09 | monomer | 100 | 1×E3B; | |||
| Crystal Structure of the Bromodomain of human CREBBP in complex with a dihydroquinoxalinone ligand | monomer | 100 | 1×SCN; 1×2O3; 2×EDO; | |||
| Bromodomain of CBP liganded with BMS-536924 and SGC-CBP30 | monomer | 100 | 1×N6I; 1×2LO; | |||
| Crystal structure of CREBBP bromodomain complexed with KD341 | monomer | 100 | 1×LSZ; 1×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1 | monomer | 100 | 1×XDM; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand | monomer | 100 | 1×2LN; | |||
| Bromodomain of CBP liganded with BMS-536924 and CCS-1477 | monomer | 100 | 1×N6I; 1×JHL; 2×EDO; | |||
| CREBBP Bromodomain in complex with Cpd17 (N,2,7-trimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-car… | monomer | 100 | 3×SO4; 1×9UG; | |||
| Crystal Structure of the Bromodomain of human CREBBP in complex with a quinazolin-one ligand | monomer | 100 | 1×15E; | |||
| Bromodomain of CBP liganded with inhibitor iCBP5 | monomer | 100 | 1×EDO; 1×YVK; | |||
| Bromodomain of CBP liganded with CCS-1477 | monomer | 100 | 3×PO4; 1×JHL; | |||
| Bromodomain of CBP liganded with BMS-536924 | monomer | 100 | 1×N6I; | |||
| Crystal structure of CREBBP bromodomain complexed with LB32A | monomer | 100 | 1×LTW; | |||
| Structure of CREBBP bromodomain with compound 2 bound | monomer | 100 | 1×JGK; | |||
| Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174 | monomer | 100 | 1×EDO; 1×SCN; 1×69A; | |||
| Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02857790 | monomer | 100 | 1×ACT; 1×CA; 1×69B; | |||
| Crystal structure of CREBBP bromodomain complexed with UT07C | monomer | 100 | 1×UT0; | |||
| Crystal structure of CREBBP bromodomain complexd with DT29 | monomer | 100 | 1×E2T; 1×EDO; | |||
| CREBBP bromodomain in complex with Cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-di… | monomer | 100 | 1×C3J; 1×EDO; 1×NA; | |||
| CREBBP bromodomain in complex with Cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-di… | monomer | 100 | 1×C3V; 2×SO4; 1×DMS; 1×GOL; | |||
| Crystal structure of CBP bromodomain liganded with CCS151 | monomer | 100 | 1×JHF; 1×EDO; | |||
| Bromodomain of CBP liganded with iCBP4 | monomer | 100 | 3×EDO; 1×YJY; | |||
| Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4 | monomer | 100 | 1×96N; 4×EDO; | |||
| Crystal structure of CBP bromodomain liganded with UMB298 (compound 23) | monomer | 100 | 1×EDO; 1×WU1; | |||
| Crystal structure of CREBBP bromodomain complexd with US13A | monomer | 100 | 1×92E; | |||
| BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide | monomer | 100 | 2×EDO; 1×TYL; 1×SCN; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine | monomer | 100 | 1×ALY; 1×SCN; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) | monomer | 100 | 1×SCN; 1×MB3; | |||
| Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory… | monomer | 100 | 1×53W; | |||
| Crystal Structure of bromodomain of human CBP in complex with the inhibitor CZL-046 | monomer | 100 | 1×A1L3S; 1×CL; | |||
| Crystal structure of the CREBBP bromodomain in complex with a benzo-diazepine ligand | monomer | 100 | 1×OS8; | |||
| Crystal structure of CREBBP bromodomain complexed with DSPB2A002 | monomer | 100 | 2×7MX; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with UP39 | monomer | 100 | 1×5QN; | |||
| Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02773986 | monomer | 100 | 1×SCN; 1×68Y; | |||
| Crystal Structure of CBP bromodomain | monomer | 100 | 1×PEG; 3×EDO; | |||
| CREBBP bromodomain in complex with Cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-di… | monomer | 100 | 1×9U4; | |||
| Crystal structure of CREBBP bromodomain complexd with PB08 | monomer | 100 | 1×E3H; | |||
| CREBBP Bromodomain in complex with Cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4… | monomer | 100 | 1×9UD; | |||
| CREBBP Bromodomain in complex with Cpd3 ((S)-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin… | monomer | 100 | 1×9U7; | |||
| Crystal structure of CBP bromodomain liganded with CCS150 | monomer | 100 | 1×EL0; 1×GOL; | |||
| Crystal structure of CREBBP bromodomain complexed with CBP006 | monomer | 100 | 1×PKU; | |||
| Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand | monomer | 100 | 2×OSQ; | |||
| Bromodomain of CBP liganded with iCBP8 | monomer | 100 | 1×YN5; | |||
| Bromodomain of CBP liganded with inhibitor iCBP2 | monomer | 100 | 1×YRI; | |||
| Crystal structure of CREBBP bromodomain complexd with DR46 | monomer | 100 | 2×AY2; | |||
| Crystal structure of CREBBP bromodomain complexed with LA36 | monomer | 100 | 1×LU5; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) | monomer | 100 | 1×SCN; 1×DMS; | |||
| Crystal structure of the CBP bromodomain in complex with CPI703 | monomer | 100 | 1×58N; | |||
| Crystal Structure of the Bromodomain of Human CREBBP | monomer | 100 | 3×EDO; | |||
| Bromodomain of CBP liganded with iCBP7 | monomer | 100 | 1×YN0; 2×EDO; | |||
| Crystal structure of the CREBBP bromodomain in complex with a tetrahydroquinoxaline ligand | monomer | 100 | 1×OSQ; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with AYC | monomer | 100 | 2×EDO; | |||
| Crystal structure of the CBP bromodomain in complex with CPI098 | monomer | 100 | 1×986; 1×EDO; | |||
| A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of hum… | monomer | 100 | 1×NO3; 1×2LL; 1×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole li… | monomer | 100 | 1×2LL; 1×NO3; 1×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole li… | monomer | 100 | 1×2LK; 1×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with ACA007 | monomer | 100 | 2×EDO; 1×LXQ; | |||
| CBP bromodomain complexed with YF2-23 | monomer | 100 | 1×YF2; | |||
| Crystal Structure of the CBP in complex with the Y08188 | monomer | 100 | 1×GAY; 1×GOL; | |||
| CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H… | monomer | 99.11 | 1×6XG; 3×EDO; | |||
| CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)am… | monomer | 99.11 | 1×6XH; 2×EDO; 1×DMS; | |||
| CREBBP bromodomain in complex with Cpd6 (methyl 1H-indole-3-carboxylate) | monomer | 100 | 2×DMS; 1×C2Y; | |||
| CREBBP bromodomain in complex with Cpd 4 (1-(1-(cyclopropylmethyl)-3-(1H-indol-4-yl)-1,4,6,7-tetrah… | monomer | 99.11 | 1×DMS; 1×EDO; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with UL04 | monomer | 100 | 1×UL4; 3×EDO; | |||
| Crystal structure of CBP bromodomain liganded with CCS1477 | monomer | 100 | 1×GOL; 1×DMS; 1×JHL; | |||
| Crystal structure of CREBBP bromodomain complexed with DK19 | monomer | 100 | 1×0BC; | |||
| Crystal structure of the bromodomain of human CREBBP in complex with XZ08 | monomer | 100 | 2×EDO; 1×XZ8; | |||
| Crystal structure of CBP bromodomain liganded with 9c | monomer | 100 | 1×JE9; 1×PO4; 1×GOL; | |||
| Crystal structure of CREBBP bromodomain complexed with CBP007 | monomer | 100 | 2×4I8; | |||
| Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold | monomer | 100 | 1×6XB; | |||
| Non-native Solution Structure of a fragment of the CH1 domain of CBP | monomer | 100 | 1×ZN; | |||
| Solution structure of Minimal Mutant 1 (MM1): Multiple alanine mutant of non-native CHANCE domain | monomer | 52.0 | 1×ZN; | |||
| Solution structure of Minimal Mutant 2 (MM2): Multiple alanine mutant of non-native CHANCE domain | monomer | 48.0 | 1×ZN; | |||
| Solution structure of Designed Functional Finger 2 (DFF2): Designed mutant based on non-native CHAN… | monomer | 48.0 | 1×ZN; | |||
| Solution structure of Designed Functional Finger 5 (DFF5): Designed mutant based on non-native CHAN… | monomer | 44.0 | 1×ZN; | |||
| Solution structure of Designed Functional Finger 7 (DFF7): Designed mutant based on non-native CHAN… | monomer | 44.0 | 1×ZN; | |||
5 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 2lqi.1.A | monomer | 0.70 | 100.00 | |||
| 6gyr.2.A | monomer | 0.61 | 3×ZN; | 87.05 | ||
| 1p4q.1.B | monomer | 0.61 | 3×ZN; | 93.75 | ||
| 8han.1.I | monomer | 0.60 | 100.00 | |||
| 8haj.1.K | monomer | 0.59 | 88.70 | |||
6 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 2lqi.1.A | monomer | 0.71 | 100.00 | |||
| Isoform 2 | 2ka4.1.A | monomer | 0.68 | 1×ZN; | 79.27 | ||
| Isoform 2 | 6gyr.2.A | monomer | 0.60 | 3×ZN; | 87.05 | ||
| Isoform 2 | 8han.1.I | monomer | 0.59 | 100.00 | |||
| Isoform 2 | 8haj.1.K | monomer | 0.59 | 88.70 | |||
| Isoform 2 | 6fgn.1.A | monomer | 0.51 | 1×ZN; | 20.39 | ||